This is a match-making section for JPIAMR 14th call - Disrupting drug Resistance Using Innovative Design (DRUID).
Human Health
in silico, in vitro, in vivo
Antibody; Antibody drug conjugate; AMR; Narrow spectrum antibiotics; superdrugs
We have developed a new class of antibacterial biologicals called AbTids that neutralize drug resistant pathogens. They ae based on a camelid antibody platform and we have POC against Pseudomonas Staphylococcus and Candida. We are looking for partners having expertise in the area for target validation and characterization ( Academic collaborations) as well as industry partners for conduction of preclinical studies and so on. Being a new class of molecule with a novel mode of action, it holds tremendous promise in both these areas development of which is very important with the looming threat of AMR pandemic
We have two molecules against a novel target in P aeruginosa that we would like to develop further. One is a camelid antibody fragment against a surface transporter and the other is an antibody drug conjugate, both of which neutralizes drug resistant P aeruginosa. We would like to collaborate with the University of Bordeaux working on he project Tackling P aeruginosa antibiotic resistance.
Submitted on 2022-02-09 18:36:21
« Return to the partner search tool